JPS6254440B2 - - Google Patents
Info
- Publication number
- JPS6254440B2 JPS6254440B2 JP56118865A JP11886581A JPS6254440B2 JP S6254440 B2 JPS6254440 B2 JP S6254440B2 JP 56118865 A JP56118865 A JP 56118865A JP 11886581 A JP11886581 A JP 11886581A JP S6254440 B2 JPS6254440 B2 JP S6254440B2
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- ifn
- acrylonitrile
- phosphate buffer
- sodium chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108090000467 Interferon-beta Proteins 0.000 claims description 28
- 102000006992 Interferon-alpha Human genes 0.000 claims description 23
- 108010047761 Interferon-alpha Proteins 0.000 claims description 23
- 102000014150 Interferons Human genes 0.000 claims description 23
- 108010050904 Interferons Proteins 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 229940079322 interferon Drugs 0.000 claims description 21
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 18
- 102000003996 Interferon-beta Human genes 0.000 claims description 15
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- 239000011780 sodium chloride Substances 0.000 description 17
- 239000008363 phosphate buffer Substances 0.000 description 16
- 102100026720 Interferon beta Human genes 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000000835 fiber Substances 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 9
- 229920002239 polyacrylonitrile Polymers 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 229920000297 Rayon Polymers 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000002964 rayon Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920006397 acrylic thermoplastic Polymers 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229940116357 potassium thiocyanate Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 229920002466 Dynel Polymers 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920002821 Modacrylic Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- -1 alkylene glycols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56118865A JPS5821691A (ja) | 1981-07-29 | 1981-07-29 | α−及びβ−インタ−フェロンの精製方法 |
| US06/385,872 US4465622A (en) | 1981-07-29 | 1982-06-07 | Method for purifying interferon |
| GB08217388A GB2111061B (en) | 1981-07-29 | 1982-06-16 | Method for purifying interferon |
| DE3223087A DE3223087C2 (de) | 1981-07-29 | 1982-06-21 | Verfahren zur Reinigung von Interferon |
| CA000406723A CA1185178A (en) | 1981-07-29 | 1982-07-06 | Method for purifying interferon |
| FR8213278A FR2510409A1 (fr) | 1981-07-29 | 1982-07-29 | Procede de purification de l'interferon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56118865A JPS5821691A (ja) | 1981-07-29 | 1981-07-29 | α−及びβ−インタ−フェロンの精製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5821691A JPS5821691A (ja) | 1983-02-08 |
| JPS6254440B2 true JPS6254440B2 (OSRAM) | 1987-11-14 |
Family
ID=14747035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56118865A Granted JPS5821691A (ja) | 1981-07-29 | 1981-07-29 | α−及びβ−インタ−フェロンの精製方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4465622A (OSRAM) |
| JP (1) | JPS5821691A (OSRAM) |
| CA (1) | CA1185178A (OSRAM) |
| DE (1) | DE3223087C2 (OSRAM) |
| FR (1) | FR2510409A1 (OSRAM) |
| GB (1) | GB2111061B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5702699A (en) * | 1982-09-23 | 1997-12-30 | Cetus Corporation | Process for the recovery of lipophilic proteins |
| US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
| US4855134A (en) * | 1983-10-14 | 1989-08-08 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release preparation |
| EP0150067A3 (en) * | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| JPS60228422A (ja) * | 1984-04-26 | 1985-11-13 | Suntory Ltd | 安定化された生理活性物質製剤 |
| JPS60243028A (ja) * | 1984-04-28 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | インタ−フエロンの可溶化方法 |
| EP0168008A3 (en) * | 1984-07-10 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| WO1986000531A1 (fr) * | 1984-07-10 | 1986-01-30 | Takeda Chemical Industries, Ltd. | Composition a base de gamma-interferon |
| US4873312A (en) * | 1985-04-25 | 1989-10-10 | Amgen | Method for purifying interferon and composition of matter produced thereby |
| DE3628468A1 (de) * | 1986-08-21 | 1988-03-03 | Thomae Gmbh Dr K | Neue applikationsformen fuer (alpha)-interferone |
| CA2024046A1 (en) * | 1989-09-28 | 1991-03-29 | Alberto Ferro | Stabilized leukocyte-interferons |
| ATE117088T1 (de) * | 1990-01-27 | 1995-01-15 | Roland Man Druckmasch | Verfahren und vorrichtung zur messung des alkoholgehalts der feuchtflüssigkeit eines feuchtwerks einer offset-druckmaschine. |
| IT1272252B (it) | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| US5861174A (en) * | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
| US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| US6433144B1 (en) * | 1999-01-12 | 2002-08-13 | Viragen, Inc. | Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods |
| EP1343518B1 (en) * | 2000-11-07 | 2009-07-22 | Novartis Vaccines and Diagnostics, Inc. | Stabilized interferon compositions |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| UY27373A1 (es) * | 2001-07-09 | 2003-02-28 | Schering Ag | Formulaciones de interferón beta-humano |
| US7367961B2 (en) * | 2004-09-10 | 2008-05-06 | Depuy Spine, Inc. | Intradiscal injection of autologous interferon |
| CN113845560A (zh) * | 2020-06-28 | 2021-12-28 | 佛山汉腾生物科技有限公司 | 目的蛋白纯化方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4810232B1 (OSRAM) * | 1970-09-04 | 1973-04-02 | ||
| FR2351665A1 (fr) * | 1976-05-21 | 1977-12-16 | Elf Aquitaine | Procede de purification de preparations possedant notamment une activite interferon, preparations purifiees ainsi obtenues et leur application en tant que medicament |
| NL7605805A (nl) * | 1976-05-28 | 1977-11-30 | Stichting Rega V Z W | Werkwijze voor het zuiveren van interferon. |
-
1981
- 1981-07-29 JP JP56118865A patent/JPS5821691A/ja active Granted
-
1982
- 1982-06-07 US US06/385,872 patent/US4465622A/en not_active Expired - Fee Related
- 1982-06-16 GB GB08217388A patent/GB2111061B/en not_active Expired
- 1982-06-21 DE DE3223087A patent/DE3223087C2/de not_active Expired
- 1982-07-06 CA CA000406723A patent/CA1185178A/en not_active Expired
- 1982-07-29 FR FR8213278A patent/FR2510409A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| CA1185178A (en) | 1985-04-09 |
| JPS5821691A (ja) | 1983-02-08 |
| DE3223087C2 (de) | 1985-11-14 |
| DE3223087A1 (de) | 1983-02-17 |
| FR2510409B1 (OSRAM) | 1984-06-22 |
| FR2510409A1 (fr) | 1983-02-04 |
| GB2111061B (en) | 1984-11-21 |
| GB2111061A (en) | 1983-06-29 |
| US4465622A (en) | 1984-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6254440B2 (OSRAM) | ||
| Yip et al. | Partial purification and characterization of human gamma (immune) interferon. | |
| US4551271A (en) | Purification of interferon by metal chelate chromatography | |
| US5503828A (en) | Alpha interferon composition and method for its production from human peripheral blood leukocytes | |
| EP1260582B1 (en) | Conjugates of factor IX and a biocompatible polymer | |
| Chua et al. | Purification of wheat proteases by affinity chromatography on hemoglobin-Sepharose column | |
| JPS59106428A (ja) | 精製された生物学的に活性なモノマ−状インタ−フエロンの製造方法 | |
| US4541952A (en) | Purification method of human interferon | |
| JP2651307B2 (ja) | 血液凝固ｉｘ因子を含有する複合体 | |
| Wiranowska-Stewart et al. | Production, partial purification and characterization of human and murine interferons—Type II | |
| EP0087686A2 (en) | Homogeneous human immune interferon and process therefor | |
| IE50075B1 (en) | Homogeneous fibroblast interferon and method for manufacture thereof | |
| Huang et al. | Selective binding of human interferon to albumin immobilized on agarose | |
| US5244655A (en) | Process for the purification of recombinant human beta interferon, beta interferon thus purified and pharmaceutical compositions which contain it | |
| EP0362298A1 (en) | Novel polypeptide having gamma-interferon activity | |
| EP0098123B1 (en) | A process for concentrating and purifying human urinary kallikrein | |
| Stewart II et al. | Effect of glycosylation inhibitors on the production and properties of human leukocyte interferon | |
| WHITMAN JR et al. | Purification of human lymphoblastoid cell-derived interferon-alpha by controlled-pore glass bead adsorption chromatography and molecular sieving | |
| Friesen et al. | [63] Purification of human fibroblast interferon by high-performance liquid chromatography | |
| KR920000051B1 (ko) | 재조합 α-인터페론의 정제방법 | |
| KR860001150B1 (ko) | 인터페론의 정제법 | |
| CA2062729C (en) | Interferon purification process | |
| JPS6150925A (ja) | 抗原または抗体の精製方法 | |
| JPS61242593A (ja) | ヒト・インタ−フエロンβの精製法 | |
| KR890001128B1 (ko) | 조 임파구 인터페론의 정제방법 |